Chrysin Ameliorates Mycoplasma pneumonia Induced Pneumonia in Mice by Down-Regulating Inflammatory Response

Background: Mycoplasma pneumonia, a major respiratory infection characterized by inflammation of the lungs, poses a substantial global health concern, particularly among vulnerable populations such as the elderly, immunocompromised individuals and young children. Objectives: The current study has focused on exploring the attenuation of Mycoplasma pneumoniae (Mp)-induced pneumonia by chrysin in rodent model. Materials and Methods: BALB/c mice were administered 1×108 (50 μL) of Mp via nasal drops to induce Mycoplasma pneumonia. The mice were then administered with chrysin (50 mg/kg) and/or azithromycin (100 mg/kg) for 3 days. Following the treatment period, the body weights of the experimental mice were evaluated. The Bronchoalveolar Lavage Fluid (BALF) was gathered from the experimental mice and subsequently subjected to analyse the total protein, total cells and inflammatory cytokine concentrations utilizing suitable diagnostic kits. The histopathological examination of the lungs was undertaken to assess histological abnormalities. Results: The treatment of chrysin markedly increased the body weight, decreased the total cell counts and total protein concentrations in the BALF of the Mp-infected pneumonia mice. Furthermore, the chrysin treatment led to a reduction in pro-inflammatory cytokine concentrations in the BALF of Mp-infected mice. The findings of the histological study exhibited a notable reduction in lung histopathological abnormalities in the chrysin-treated mice, which evidenced the therapeutic potentials of the chrysin against pneumonia condition. Conclusion: The results of this study highlight the beneficial effects of chrysin against Mycoplasma pneumonia in mice due to its potential anti-inflammatory properties. Thus, chrysin can be a viable salutary candidate to treat pneumonia.